StockData
Protagenic Therapeutics, Inc.new logo

Protagenic Therapeutics, Inc.new (PTIX) stock

PTIXOTCPharmaceutical PreparationsFiscal year ends March 31
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026
$0.75+0.00 (0.00%)

Close on Oct 19, 2026Market cap $1.36MP/E –Yield –

Protagenic Therapeutics, Inc.new reported revenue of $0 for the twelve months to Dec 31, 2024. At the latest close the market valued the company at $1.36M.

Revenue
$0
TTM Q4 2024
Operating income
-$5.70M
TTM Q4 2024
EPS, diluted
-$15.82
TTM Q4 2024

Key statistics

Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026

Valuation

Market cap
$1.36M
P/E ratio
–
Price to sales
–
Price to book
0.79
Dividend yield
–
Free cash flow yield
–

Fundamentals

Revenue
$0
Net income
-$5.53M
EPS, diluted
-$15.82
Book value per share
$0.95
Diluted shares
2M

Trading

Previous close
$0.75
Open
$0.76
Day's range
$0.75 – $0.76
Volume
1,262
Average volume (20 days)
1,624

Market cap history

Month-end market cap since 2021, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.

PeriodPTIXS&P 500DifferencePTIX per yearS&P 500 per year
1 month-18.0%+0.6%−18.6 pts
3 months+188.5%+3.4%+185.1 pts
Year to date-42.3%+13.3%−55.6 pts
1 year-76.7%+16.6%−93.3 pts
3 years-93.9%+86.4%−180.3 pts-60.7%+23.1%
5 years-99.3%+81.9%−181.2 pts-62.9%+12.7%

Eleven years at a glance

Fiscal years 2013 to 2024, USD

Revenue

$0

Operating income

-$5.70M

Net income

-$5.53M

EPS, diluted

-$15.82

Free cash flow

–
Reported period

Press releases

Releases Protagenic Therapeutics, Inc.new filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Protagenic Therapeutics, Inc.new

Pharmaceutical Preparations

Protagenic Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing therapeutics for stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of Teneurin Carboxy-terminal Associated Peptide-1 (TCAP-1), designed to counter excess stress signaling. The company targets conditions including treatment-resistant depression, substance use disorder, generalized anxiety disorder, and post-traumatic stress disorder. Through a prior reverse merger with Phytanix Bio, historical drug candidate programs also encompass preclinical assets such as potassium channel modulators, cannabinoid-based therapies, and modified stilbenoid compounds.

Company profile, executives and history

Protagenic Therapeutics, Inc.new stock: common questions

What is Protagenic Therapeutics, Inc.new's stock price?

PTIX closed at $0.75 on Oct 19, 2026, up 0.00% on the day.

What is Protagenic Therapeutics, Inc.new's market cap?

Protagenic Therapeutics, Inc.new was worth $1.36M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.

What is PTIX's P/E ratio?

Protagenic Therapeutics, Inc.new lost money over the twelve months to Dec 31, 2024 (diluted EPS -$15.82), so it has no meaningful P/E ratio.

How much revenue does Protagenic Therapeutics, Inc.new make?

Protagenic Therapeutics, Inc.new reported revenue of $0 for the twelve months to Dec 31, 2024.

Does Protagenic Therapeutics, Inc.new pay a dividend?

No. Protagenic Therapeutics, Inc.new has not paid a cash dividend over the last twelve months.

How has PTIX stock performed over the past year?

Including dividends, PTIX returned -76.7% over the past year, against +16.6% for the S&P 500.

Who are Protagenic Therapeutics, Inc.new's competitors?

Companies most similar to Protagenic Therapeutics, Inc.new by business, industry and size include CMPS, PBM, ENVB, VTGN, XENE.

See a number that looks wrong?